FDA names Scott Steele acting head of CBER after Marks’ ouster 

Scott Steele has been named acting director of FDA’s Center for Biologics Evaluation and Research following the ouster of longtime CBER Director Peter Marks. Prior to his appointment as acting director, Steele served as senior adviser for translational science in CBER’s Office of Center Director.
FDA has not named replacements for senior staff who were pushed out on April 1. Unfilled vacancies include director of the Office of New Drugs at the Center for Drug Evaluation and Research and FDA Chief Medical Officer. Peter Stein had served as OND director since 2018. Hilary Marston was named CMO in 2022. Stein and Marston resigned rather than accept demotions.

The appointment of new managing directors Matt Cohen and Brian Goodman at Vida Ventures will once again bring the firm’s total to five in that position. Cohen joins from J.P. Morgan Asset Management, while Goodman was most recently a partner at MPM BioImpact...